Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well people will slowly dump their shares. I am getting pi$$ed myself. Now we are back to .0001 and management doesnt give a rats a$$. Sorry for being so negative. I supported the stock through thick and thin. I am done. I am not sure how much longer I can wait. This is a huge disappointment - support from management is pathetic. There is no way to even get in touch with anyone. Feels like we are all alone hanging on to a sinking ship. Sorry - but I am getting worn out from this.
Mash
Agree and the worst part is there is no way to get ahold of anyone. There is no support of any kind. What are they thinking?
This is getting OLD!!!
Mash
Wonder why someone would buy 2 million shares of a dead stock?
Guess someone believes. Maybe it will be revived.
THIS IS RESPONSE TO A MESSAGE ON YAHOO MESSAGE BOARD:
There are a thousand reasons to sell a stock but only one reason to buy. Monday morning the stock suffered a severe drop early on because of a 100,000 share market order before recovering late in the session as cooler heads (no pun intended) prevailed. With a thin stock such as WARM, a market order of this size will cascade down through all existing Buys. No sophisticated investor would ever sell in such a fashion so one could hardly take this action as a proxy of an enlightened opinion on the stock or the company. If you were the expert you attempt to portray, then you would already know this
So far we have yet to see any results, positive or negative, confirming or denying the reason we invested in WARM in the first place. Big rewards come with risks & volatility as part of the territory at this stage. You could choose to sit on the sidelines until the situation becomes more certain, such as a major order announced, however then you will be paying $5-7 but 90% of the risk AND reward will be gone.
By what you’ve written, it is 100% clear to me you are frustrated. However frustration does not lead to good decision making, especially in stocks. It is also clear you have not been directly involved in large scale commercial manufacturing and product rollout. With regards to patents, you demonstrate a surprising lack of knowledge concerning the WARM patents and how they are applied. Warm's patents are utility patents, not product patents. They cover the use of heat pipes in certain applications. They are stronger and more easily defensible than product patents. Were you actually in the industry you would already know the difference so again we can discount your "analysis".
Isn't it amazing what you can come up with in 5 minutes of Google research? Unfortunately this does not then make you a presumed expert on the subject. I think the old saying is, "A little bit of knowledge can be a dangerous thing"... especially for investors.
In your in-depth research you uncovered that NASA has indeed used heat pipes. To be somewhat more accurate however, NASA uses and used heat pipes in a “static” application. This is completely different from using heat pipes in rotating equipment.
Heat pipes have been around since the 1890s and used in many applications prior to NASA. You probably have one in your hand right now in your smart phone. Static applications such as NASA used have been around and executed since the early 1920's. If you truly understood the Cool Tech patents and target applications, you would not have brought up a static application and your technical reference to "Zero Gravity" shows your complete lack of understanding of basic thermodynamics.
Further, if you take a look at the team at Cool Tech, each has different roles and responsibilities. Someone with just a little knowledge of corporate structure would understand this. It is odd you selected Cool Tech as an investment given you exhibit no practical experience in R&D or how to commercialize a product. You typically get one chance when playing in the big leagues. Making sure you have the best possible chance falls on management and this process sometimes takes longer than expected but if you are trying to change an industry paradigm and a product class, you only have one bite at the apple so you better make it work the first time.
You mention a "failed" Navistar executive on the board. Hmmm, 37 years of a great career, but of course you would know better because you have Google... I guess that would also rule out Carly Fiorini as well? The Siemens person you refer too on the advisory board, is a 43 year career veteran of Siemens Energy and automation and is their CTO. He is or has been either the Charmian or vice chairman of nearly every international standards board. The guy is basically a rock star in motors and generators. But again, you with all of your vast experience (& Google) know better.
Actually, one would think such prestigious veterans of an industry would not back a company and its management team if they did not believe there would be execution of product built on great technology. Why else would any of these guys waste their time on such a small company? After all, they all have succeeded tremendously in industry because they did execute. They must likewise believe WARM will deliver or why bother.
The company is hardly perfect nor would I expect an early development phase company to run like GE. Obviously events have conspired to the net effect of progress happening slower than hoped for. Too much time wasted in lawsuits but that is all finally in the past. The company remains one major contract away from becoming a huge success. When contract announcements begin, you will not be able to get in cheaply any longer. I can't wait to hear the sour grapes then, "I wish I had picked up more when it dropped". Stocks like these go up and down because it is thinly traded at this point. As the price rises there will be more liquidity emerge but not likely till the $5 plus area. There is an old saying that I've found to be true over the years, "you always own too much of the ones that don't go and not enough of the ones that do". For once I would like to be on the other side of that saying...
A complete addenda to the financials will be published at a later date, to include information as to the
lawsuit, settlement with subcontractor and repayment of company debts accumulated during the
lawsuit.
Looks like the doors are barely open. Are there any positives here? Mash
Where is our late filing for today? Am I missing it?
Thanks
Mash
Hi bag holders
Seriously I keep adding to my bag.
I would like to know if there is a date for earnings that are due this month.
Thanks and always wish everyone best. We all deserve success for being so faithful and patient.
Mash
PS I never received a response to my note to management. Guess I don't count. ;-(
Hi Peg,
Probably just welcoming you back. You disappeared for a bit and we missed you.
Mash
PS I wrote to management a week ago - no word yet. If and when I get a response, I will post.
EVERMEDIA SETTLES LAWSUIT AGAINST FORMER COMPANY OFFICERS
June 16, 2015 at 10:25pm
FOR IMMEDIATE RELEASE:
Boston—June 17th, 2015
The Evermedia Group, Inc. announces that it has settled its lawsuit against two former Company officers, Richard Weitzel and Patricia Waldroop. Two years ago Evermedia filed a lawsuit against former Evermedia Co-President Richard Weitzel and Corporate Secretary Patricia Waldroop, alleging misappropriation of funds, breach of fiduciary duties, embezzlement and conversion, among other claims.
“The decision to settle the lawsuit and not proceed with trial was difficult due to the egregious nature of the acquisitions cited in Evermedia’s claims. Despite the tribulations in regards to settling, we believe it was the right business decision.” said Jonathan Sym, CEO of The Evermedia Group, Inc. “After we deposed Weitzel and Waldroop, we were convinced that our case was solid and we were anxiously awaiting our day in court. However, due to inefficiencies and long delays in our legal system, we decided that it was in the best interest of our shareholders to settle this civil matter. Even after terms were finalized, agreed to, and the motion filed into the public record, it took several months to realize the effects of the settlement.”
The settlement was a compromise in which Evermedia received a net cash award of nearly $304,000, a confession and apology from Richard Weitzel, and the return of all shares of Evermedia stock owned by Weitzel and Waldroop. In exchange, Evermedia agreed to drop the civil lawsuit against both defendants and relinquish a sum of $76,000 as well as issue mutual releases. There were two other issues related to the suit that were recently discharged, an invoice and a meeting. Moreover, there was a dispute over property related to STS operations that was resolved Monday, June 15th. Management wanted to finalize all matters that were of concern, whether they were directly or indirectly related with the settlement terms, before publishing a press release for our shareholders. Due to the numerous delays and setbacks, management felt it was important to have everything in place before reporting the terms.
Since many shareholders have expressed an interest for greater detail in regards to the circumstances of our lawsuit, the Company will be publishing further information in the months to follow. Additional postings will be published primarily through Evermedia’s social media platforms and sent via email to interested shareholders. Additionally, a detailed summary of the lawsuit and settlement terms will be published on OTC Markets at a later date.
Over the last several months management has forged new relationships in the biometric sector that our team and partners are enthusiastic to develop. In addition, management has eliminated nearly all of our debt, has continued to strengthen current relationships, explored new investment opportunities in emerging social markets and sought to diversify Evermedia’s revenue streams. Though there is a great deal of excitement about our future, leadership remains cautiously optimistic and patient in the development and execution of our corporate vision. As a small, publicly traded company that desires a larger footprint in our business sectors, it is imperative that we administratively and operationally focus on becoming leaner and much more efficient, to be more productive with less resources and to continue to support our people.
On a personal note, this lawsuit has been very trying both from an individual and a professional standpoint. At the end of 2012, we reached a company milestone; nearly $3M in revenues, offices in two states and two countries, blue chip clients and 15 employees. The last two years have been the darkest times in our company’s history; a trillion dollar sequestration, disloyal employees putting their personal interests ahead of others, and significant cutbacks in federal biometric spending. These left us with not only minimal options and resources but also a tremendous amount of work and obligations. We are stronger, and certainly wiser, today. I look forward to working together for a stronger future.
I want to personally thank you, our supportive shareholders, for your patience and encouragement. I want to thank our attorney, Kyle Watson, and his staff for their wisdom and guidance. I want to thank our clients who understood our situation and continued to provide us with meaningful business. I want to thank our Directors and corporate partners who have continued to strengthen our belief and resolve. I also want to thank our Evermedia team; Larry Cardinal, who continues to bring leadership into our projects, to David T. and Randall N. for pushing hard and always delivering quality service to our customers, and to Robert Skinnion for his insightful research and dedication to our company. Most of all I want to thank my family for believing in our efforts and never giving up.
Thank you and God bless.
-JS
Just doing my part to support the company.....
Best
Mash
Yes, thank you for any updates.
Mash
Notes to Financial Statements:
1)
The $89,750 disputed invoice included in the liabilities section was resolved in Quarter 2 of this year. While not reflected in the Q1 Statement, payment was issued to the subcontractor
about a week ago. The amount settled upon was $12,000.
With this settlement, the majority of the debt held in the liabilities section is internal debt, consisting mostly of accrued salary by front office employees and loans to the company by Mr. Sym. A portion of the remaining debt is legal bills that have accumulated through the settlement process.
2)
The difference in amount between the cash balance at the end of the last fiscal year and the cash amount at the beginning of this fiscal year is the sum contained in a petty cash checking
account that had been omitted and represents about 390 dollars.
3)
Settlement details are not contained in this report either as an addenda or within the financials. While terms were agreed upon during the latter portion of Q1, completion of the agreed upon items continued through Q2. The Company will be issuing a statement as to the settlement terms shortly. It was anticipated that this would have been completed earlier, but there were a few small hold ups along the way to the final agreement. Due to multiple delays and false starts throughout the entirety of the mediation/settlement process, the Team felt it was important to wait until everything was in hand before reporting terms. Due to the length and nature of the lawsuit, it did not seem appropriate to report anything that had been agreed upon until completion of the process. This was due in large part to the nature of the negotiations and how advancement towards a final result had developed
I added but still unsure of future.
Best to all.
Mash
Thanks. I was the lucky one to get 7's.
muah.
mash
I agree but first, we need new buyers.
Best Mash
That with "prejudice" says a lot. Thank goodness it is over and done with. Should be behind us sooner than later. Best to all shareholders. We have been in this together for a zillion years (feels like it!!).
Mash
I just called the court house to see if there is an outcome. Jury trial was in January but there are no final orders. She said no word when that will be. That was all I could find.
Best.
Mash
Yes Shadow, thanks so much for contribution. It was all very much needed and I am sure appreciated by all.
Thanks to all the supporters not just in buying but in moral support. We have had a very rough ride but we are here because we believed. Again, great A team. Now we will wait to hear from our company exec.
Best to all of us.
Mash
SWEET!!!!!! Hopefully wont take so long to get going.
Mash
What's going on? That is a ton of volume for this sound sleeper!
Am surprised it is holding .0005 with that volume.
best
Mash
Hi Harry
Sure will increase when you buy a boatload.
I was thinking that since the qtr report will be done end of this month, it means they are still in business. If they were going to go down, why would they pay for doing the quarterly or year end which it is? I look at that as a sign "we are still moving along". Any comments?
So Harry, really buy a bunch and join us bag holders, or heavy investors.
Best to all.
Mash
I agree totally.
mash
Thanks. I am all in. Waiting for COOL change and more.
Best to all of us
Mash
Hi - guess we are truly bag holders (or us holding on).
Does anyone see where the bottom is? I cannot find any news.
What is causing this haircut?
Thanks
Mash
Surprised no one is buying.
Mash
Can anyone please give chart advice? Where is next support? Looks like 5.13 is our resistance once we turn? Thanks.
Mash
Norm,
Thanks so much for taking the time to help me sort through this stock. I am learning a lot but will die dumb, I am sure. It has helped understand a little more of the process and how things are in the real market world.
Again, I appreciate much.
Mash
Well that was a harsh lesson but I learned from your posts.
This was a first holding into approval. Boy -- learned the hard way.
I see that 5.16 was support. At one point do we start back up? or is that never after approval. Sorry = newbie to bios. UGH
Thanks again for the lesson.
Mash
PS I was so excited about approval I had my money spent. WRONG.....
As I said, it is from yahoo message finance board for OREX. Nothing to back it up though.
is this true???
yahoo....
Just out!!!! Watch The Wires_The FDA Has Approved Contrave, The Leading Pipeline Drug Of Orexigen Therapeutics (OREX) Predicts Sierra World Equity Review
.
Where are monitors? DOO stop posting your zzzz. thanks
from yahoo...
OREX just tipped their hand. Contrave is getting approved.
.
Look at the 8-k. Why else would they file it. Load up the truck folks. Not very often do you get a gift like this.
Form 8-k filed
.
http://archive.fast-edgar.com/20140908/AJ2ZG22FZW2RETZK222E2ZXQBU2DZZ22ZS62
Sentiment: Strong Buy
So many Z's and Wednesday is the hearing, is that correct?
Best,
Mash
Yes and looks like last trade 5.98. Wonder if something other than approval coming?
Possible Delay In Orexigen Approval Process In Europe
Jul. 31, 2014 9:54 AM ET | About: Orexigen Therapeutics, Inc. (OREX), Includes: ARNA, VVUS
Disclosure: The author is long ARNA. (More...)
Summary
Competitors Belviq and Qsymia have not had success in Europe.
Orexigen proposes 30 day extension on Europe application.
Orexigen still positive on prospects in Europe.
Orexigen (NASDAQ:OREX) announced on July 30 that the company has received a List of Outstanding Issues (LOI) in the form of a 180 day Letter from the Committee for Medical Products For Human Use (OTCQB:CHMP) regarding the anti-obesity drug Contrave. The company disclosed that the LOI included new issues that were not brought up previously in the 120 day letter the company had previously addressed. Orexigen also stated that CHMP wanted additional information regarding the suppliers of components in the drug.
This article was sent to 4,210 people who get email alerts on OREX.
Get email alerts on OREX »
While the company expressed that it remained positive on the prospects of drug approval in Europe, the new issues were substantial enough that Orexigen is seeking a 30 day extension. Orexigen disclosed that it feels that tests in its Light Study can address most of the concerns raised by CHMP, but that in order to compile information from suppliers that more time was needed. As a result the company plans to respond to the 180 day letter in September.
These statements from the company seem to make logical sense, but one has to wonder about the timing. The proposed answer to CHMP now falls after the September 11th date that the company is anticipating a decision from the FDA on the same drug.
Orexigen is the third player to make an attempt at getting approval for an anti-obesity drug in Europe. Vivus (NASDAQ:VVUS) sought approval for Qsymia, was rejected, and then rejected again on appeal. Arena Pharmaceuticals (NASDAQ:ARNA) withdrew its application rather than face what was slated to be a rejection. Risk vs. Reward was a big component in the process for both Arena and Vivus. That same dynamic was also brought up in the LOI for Contrave.
It is certainly possible that Orexigen can ultimately gain approval, but the fact that new issues have been raised with the 180 day LOI that in many ways mimic the experiences of Vivus and Arena give reason for pause. Is it possible that Contrave meets with ultimate failure in Europe like its counterparts Vivus and Arena? I think investors owe it to themselves to consider that as the ultimate outcome.
If we take a conservative approach to this and assume that Europe will not approve, then some of the potential value in the equity is undermined. While the bullish investors may not appreciate this thinking, there is enough previous experience to warrant erring on the side of being more conservative.
In my opinion the pending FDA decision in the United States is more important than ever now. Prospects of U.S. approval look good in that the delay of the U.S. decision is said to be negotiations regarding post marketing requirements. The fact that the negotiations seem to be at the post marketing level would seem to indicate that an approval is very possible depending on an agreement of what types of studies will be required after approval.
Sales of competing drugs already on the market in the United States have not been anywhere near the levels expected by the street. The thought that Orexigen could be the first of the three approved in Europe was something that intrigued many. With this news today some of the thunder has disappeared for the near term. Stay Tuned!
This article was sent to 4,210 people who get email alerts on
http://seekingalpha.com/article/2263303-fda-delays-decision-on-orexigen-anti-obesity-drug-what-this-means-to-the-stock?app=1
FDA Delays Decision On Orexigen Anti-Obesity Drug - What This Means To The Stock
Here is the detail SAN DIEGO, July 30, 2014 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced it has received the Day 180 List of Outstanding Issues (LOI) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained release (SR) / bupropion SR) is an investigational drug candidate being evaluated for weight loss.
The key questions of the earlier Day 120 time point were adequately addressed by the Company based in part on the interim analysis of the Light Study cardiovascular outcomes trial. However, the Day 180 LOI raised new issues. Specifically, the CHMP requested further justification of the balance of benefits and risks of NB32 treatment as well as additional information regarding post-approval risk minimization measures and pharmacovigilance activities. Details were also requested of the Company's third-party suppliers of bupropion related to their starting materials.
The Company believes the CHMP's requests are addressable. However, in regards to the third-party suppliers, in order to have the time to coordinate responses from these suppliers, Orexigen has requested an extension of one month and plans to submit its response to the Day 180 LOI in September.
"We believe NB32 has a benefit risk profile that supports approval, and we are confident in our ability to justify its profile to the CHMP," said Michael Narachi, CEO of Orexigen. Less
thanks Morg. That is very disturbing in itself.
Mash